HemCon Medical Technologies ("HemCon"), a global innovative developer of advanced medical technologies and products, has recently partnered with ENTrigue Surgical, Inc. ("ENTrigue"), a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon's latest breakthrough product, a hemostatic surgical gel. Synaero Hemostatic Gel, based on HemCon's proprietary oxidized cellulose platform, is a hemostatic gel to be used during and after ENT surgical procedures to control bleeding, minimize edema and prevent adhesions.
“Synaero is the perfect complement to ENTrigue's extensive line of otolaryngology products and they are a strong partner in the industry having gained the trust of clinicians with their expertise.”
ENT surgical procedures are adopting a "less-invasive" surgical approach to reduce trauma and post-surgical patient discomfort. Synaero Hemostatic Gel is designed to be easily administered endoscopically to the nasal cavity and lightly coat the mucosal tissue to control bleeding. This eliminates the need for nasal packing to control bleeding, giving surgeons clear visibility of the surgical field, allowing for more precise and faster procedures, as well as increased patient comfort.
"HemCon is proud to be leveraging one of its platform technologies and expanding its hemostatic product offerings into the ENT surgical world," said John W Morgan, President and CEO of HemCon. "Synaero is the perfect complement to ENTrigue's extensive line of otolaryngology products and they are a strong partner in the industry having gained the trust of clinicians with their expertise."
The Synaero surgical gel is the first of a number of additional gel-based products that HemCon will be introducing to the surgical and broader healthcare markets.
Synaero Hemostatic Gel will be showcased during the upcoming American Academy of Otolaryngology Annual Meeting in Boston September 26-29, 2010 in the ENTrigue booth.
Source : HemCon Medical Technologies